| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CEMI Stock Overview
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases.
Chembio Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.87 |
| 52 Week High | US$3.38 |
| 52 Week Low | US$0.42 |
| Beta | 1.65 |
| 1 Month Change | 9.09% |
| 3 Month Change | 45.00% |
| 1 Year Change | -64.63% |
| 3 Year Change | -83.74% |
| 5 Year Change | -85.85% |
| Change since IPO | -99.43% |
Recent News & Updates
Chembio stock rises 13% amid plans to develop rapid test for monkeypox
Chembio Diagnostics (NASDAQ:CEMI) said it is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. The company added that it is exploring the technical requirements for test development using its technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners. "We are in dialogue with leading health organizations at the federal and state level to evaluate the need for a rapid test to detect and diagnose monkeypox. We are assessing the market needs, timing, regulatory pathway and investment required to develop a test," said Chembio's President and CEO Richard Eberly. CEMI +12.64% to $0.98 premarket Aug. 16
Shareholder Returns
| CEMI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -15.5% | 2.3% | 3.6% |
| 1Y | -64.6% | -19.6% | -9.6% |
Return vs Industry: CEMI underperformed the US Medical Equipment industry which returned -19.1% over the past year.
Return vs Market: CEMI underperformed the US Market which returned -10.2% over the past year.
Price Volatility
| CEMI volatility | |
|---|---|
| CEMI Average Weekly Movement | 17.2% |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CEMI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: CEMI's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 337 | Richard Eberly | https://chembio.com |
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases.
Chembio Diagnostics, Inc. Fundamentals Summary
| CEMI fundamental statistics | |
|---|---|
| Market Cap | US$26.30m |
| Earnings (TTM) | -US$36.08m |
| Revenue (TTM) | US$60.61m |
0.4x
P/S Ratio-0.7x
P/E RatioIs CEMI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEMI income statement (TTM) | |
|---|---|
| Revenue | US$60.61m |
| Cost of Revenue | US$50.71m |
| Gross Profit | US$9.90m |
| Other Expenses | US$45.97m |
| Earnings | -US$36.08m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 16.33% |
| Net Profit Margin | -59.52% |
| Debt/Equity Ratio | 96.1% |
How did CEMI perform over the long term?
See historical performance and comparison